pindolol has been researched along with Panic Disorder in 3 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to determine the efficacy of pindolol as an augmentor of fluoxetine in treatment-resistant panic disorder (PD)." | 9.09 | Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. ( Dannon, PN; Dolberg, OT; Grunhaus, L; Hirschmann, S; Iancu, I; Zohar, J, 2000) |
| "The objective of this study was to determine the efficacy of pindolol as an augmentor of fluoxetine in treatment-resistant panic disorder (PD)." | 5.09 | Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. ( Dannon, PN; Dolberg, OT; Grunhaus, L; Hirschmann, S; Iancu, I; Zohar, J, 2000) |
| "the β-adrenergic and 5-HT(1A) receptor antagonist pindolol has been used in combination with antidepressant drugs, to shorten the time of onset of clinical efficacy and/or increase the proportion of responders in depressive and anxiety disorders." | 3.76 | Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze. ( Audi, EA; Graeff, FG; Roncon, CM; Sela, VR; Zangrossi, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernik, M | 1 |
| Ramos, RT | 1 |
| Hetem, LAB | 1 |
| Graeff, F | 1 |
| Sela, VR | 1 |
| Roncon, CM | 1 |
| Zangrossi, H | 1 |
| Graeff, FG | 1 |
| Audi, EA | 1 |
| Hirschmann, S | 1 |
| Dannon, PN | 1 |
| Iancu, I | 1 |
| Dolberg, OT | 1 |
| Zohar, J | 1 |
| Grunhaus, L | 1 |
2 trials available for pindolol and Panic Disorder
| Article | Year |
|---|---|
Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients.
Topics: Adult; Anxiety; Female; Fenfluramine; Flumazenil; GABA Modulators; Humans; Male; Middle Aged; Panic | 2019 |
Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Anti-Anxiety Agents; Double-Blind Method; | 2000 |
1 other study available for pindolol and Panic Disorder
| Article | Year |
|---|---|
Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze.
Topics: Adrenergic beta-Antagonists; Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; D | 2010 |